Gu Jieruo

[Expert Profile] Gu Jieruo, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in ankylosing spondylitis and gout in China, working in the Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University. She has long been dedicated to the clinical diagnosis, treatment, and translational research of ankylosing spondylitis, genetic-related rheumatic diseases, and gout, and is an important leading figure in rheumatology in China.

[Education & Career] Professor Gu Jieruo graduated from Sun Yat-sen University of Medical Sciences, completed systematic clinical training at the Third Affiliated Hospital of Sun Yat-sen University, and further studied at famous international rheumatology centers, systematically mastering molecular genetics and clinical research methods for rheumatic diseases. She has long served as Director of the Rheumatology Department at the Third Affiliated Hospital, holding important academic positions including Vice Chair of the Rheumatology Branch of the Chinese Medical Association. She has presided over major projects including key grants from the National Natural Science Foundation of China and the National Key R&D Program, and has achieved a series of original results in genetic research on ankylosing spondylitis.

[Areas of Expertise] Professor Gu specializes in early diagnosis and standardized treatment of ankylosing spondylitis (AS), risk assessment and precise management of genetic-related rheumatic diseases, and the diagnosis and treatment of various rheumatic diseases such as gout and rheumatoid arthritis. She has extensive experience in genetic susceptibility gene testing interpretation (such as HLA-B27), imaging assessment of spondyloarthritis, and individualized biologic application. She excels at managing "familial low back pain" and other genetic-related rheumatic cases, helping numerous ankylosing spondylitis patients achieve early diagnosis, standardized treatment, and delayed disability.

[Academic Achievements & Industry Contributions] Professor Gu has achieved outstanding results in genetic and clinical research on ankylosing spondylitis, systematically studying the mechanisms of HLA-B27 and related susceptibility genes in Chinese populations, with findings published in top international journals, providing important basis for precise subtyping and early warning of ankylosing spondylitis. She has led the development of Chinese ankylosing spondylitis and gout diagnosis and treatment guidelines and expert consensus statements, actively promoted standardized biologic application and whole-course patient management, and led multi-center clinical trials, significantly improving the overall prevention and treatment level of spondyloarthritis and gout in China, and making important contributions to rheumatology development.

[Clinical Practice & Outstanding Contributions] Professor Gu has long held dedicated ankylosing spondylitis and gout clinics, cumulatively treating tens of thousands of related patients, with patient coverage extending nationwide and among overseas Chinese communities. Leading her team, she has established a whole-course management system for ankylosing spondylitis, preserving spinal function and life futures for countless young patients. She is enthusiastic about science popularization and public welfare, having repeatedly organized patient education activities, and is deeply trusted and loved by patients. She is an outstanding expert in the field of ankylosing spondylitis prevention and treatment in China.

[Honors & Reputation] Professor Gu Jieruo serves as Director of the Rheumatology Department at the Third Affiliated Hospital of Sun Yat-sen University and Vice Chair of the Rheumatology Branch of the Chinese Medical Association, among other academic positions. She has presided over national-level projects including the National Key R&D Program, and is a discipline leader in rheumatology in southern China. She has achieved outstanding results in clinical and genetic research on ankylosing spondylitis and genetic-related rheumatic diseases. She has led the establishment of a national ankylosing spondylitis clinical cohort and genetic database, promoted the implementation of susceptibility gene testing and standardized diagnosis and treatment, and has research findings published in international authoritative journals, receiving multiple science and technology awards. For decades on the clinical front lines, she has helped numerous ankylosing spondylitis patients achieve early diagnosis and standardized treatment, and is deeply trusted by patients and respected by peers alike.